NextGen Biomed (XTAE:NXGN) Growth Rank : 0 (As of Jun. 07, 2024)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Growth Rank?

NextGen Biomed has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

NextGen Biomed Growth Rank Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.